Dasatinib

Leukemia drug dasatinib promising for skin, breast, and other cancers

By

The leukemia drug dasatinib shows promise as a treatment for skin, breast, and several other cancers, according to new research.

Dasatinib thwarts brain cancer metastasis after bevacizumab use

Combining the antiangiogenic bevacizumab with the kinase inhibitor dasatinib stopped glioblastoma metastasis after shrinking the tumors.

Investigational drug is active against the most resistant types of chronic myeloid leukemia

By

A previously invincible mutation in chronic myeloid leukemia has been thwarted by the investigational drug, ponatinib, in a phase I clinical trial.

Optimal dose of dasatinib determined for advanced, recurrent ovarian cancer

By

A phase I trial determined that dasatinib 150 mg daily is the optimum dose when dasatinib is combined with paclitaxel and carboplatin to treat patients with advanced or recurrent ovarian cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs